Pharmaceuticals

Neurocrine Bio takes aim at epilepsy with $50 million acquisiton

7 monthes ago   |   By San Diego Biotechnology

Collaboration with Xenon Pharmaceuticals seeks to commercialize treatment for the disease...
Read more ...

 

Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy

Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy

7 monthes ago   |   By Xconomy

Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder. The Xenon deal is the second one San Diego-based Neurocrine has struck this year in a bid to expand the landscape of neurological disorders for which it can offer treatment. For its $50 million, Neurocrine gets the rights to Xenon's experimental treatment for a rare, hereditary form of early-onset epilepsy caused by mutations to the gene SCN8A...
Read more ...

 


Search by Tags

   Pharmaceuticals      Pharmaceutical      News      Pharma      Drug      Brain      Biosciences      Drugs      Neurology      Clinical      Gene      Genes      National blog main      San Diego      San Diego blog main      San Diego top stories      AbbVie      Biotech      Clinical trials      Deals      Epilepsy      FDA      Financing      Licensing      Life Sciences      Neurocrine Biosciences      Pipeline      Research collaboration      Xenon Pharmaceuticals  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

Foghorn Therapeutics could receive up to $425 million in the development deal with Merck, its first partnership with a major biopharma. One way that a cell regulates which... Read more ...

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based... Read more ...

Data Migration: Being Prepared

Data Migration: Being Prepared

Our Professional Services Written by: Alan Pham, Business Development Associate In a world where our data is crucial to our everyday lives, implementing new platforms is... Read more ...

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

The first drug for neurofibromatosis type 1 is available to patients following the FDA's approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection... Read more ...

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has... Read more ...

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

Biogen Alzheimer's Drug in FDA's Court Following Completion of Filing

By early September Biogen-plus the many scientists, patients, and investors following the saga of its controversial Alzheimer's drug aducanamab-should know whether the FDA... Read more ...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

The 2020 National Xconomy Awards - celebrating the best in biotech innovation and entrepreneurship - just got bigger! We're excited to announce the expansion of the 2020... Read more ...

Scientists Dive Deep Into Hidden World of Quantum States

Scientists Dive Deep Into Hidden World of Quantum States

Right: Animation of a Van Hove singularity shown approximately 1 nanometer below the surface of an oxide heterostructure made of atomically thin layers of strontium titanate... Read more ...

UFGI Publication round-up week 7/6/20

Manipulation of sensory characteristics and volatile compounds in strawberry fruit through the use of isolated wavelengths of light. Campbell SM, Sims CA, Bartoshuk LM... Read more ...

DNA Chisel, a versatile sequence optimizer

AbstractMotivationAccounting for biological and practical requirements in DNA sequence design often results in challenging optimization problems. Current software solutions are... Read more ...